These outcomes may vary with CAR constructs and tumor types [81], but since iCD4+ T cells faithfully recapitulate many functional features of primary CD4+ T cells, it is reasonable to expect that iCD4+ T cells could be effective in tumor settings where primary CD4+ T cell–based therapies have shown clinical benefit. This evidence concerns the gene CD4 and neoplasm.